These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18362292)

  • 21. Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without pegvisomant.
    Neggers SJ; van Aken MO; de Herder WW; Feelders RA; Janssen JA; Badia X; Webb SM; van der Lely AJ
    J Clin Endocrinol Metab; 2008 Oct; 93(10):3853-9. PubMed ID: 18647806
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term efficacy and safety of combined treatment of somatostatin analogs and pegvisomant in acromegaly.
    Neggers SJ; van Aken MO; Janssen JA; Feelders RA; de Herder WW; van der Lely AJ
    J Clin Endocrinol Metab; 2007 Dec; 92(12):4598-601. PubMed ID: 17895318
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly.
    Auriemma RS; Grasso LF; Galdiero M; Galderisi M; Pivonello C; Simeoli C; De Martino MC; Ferrigno R; Negri M; de Angelis C; Pivonello R; Colao A
    Endocrine; 2017 Mar; 55(3):872-884. PubMed ID: 27295183
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
    Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The metabolic profile in active acromegaly is gender-specific.
    Ciresi A; Amato MC; Pivonello R; Nazzari E; Grasso LF; Minuto F; Ferone D; Colao A; Giordano C
    J Clin Endocrinol Metab; 2013 Jan; 98(1):E51-9. PubMed ID: 23162101
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
    Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
    Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly: six-month report on an Italian multicenter study. Italian Multicenter Slow Release Lanreotide Study Group.
    Giusti M; Gussoni G; Cuttica CM; Giordano G
    J Clin Endocrinol Metab; 1996 Jun; 81(6):2089-97. PubMed ID: 8964833
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular consequences of early-onset growth hormone excess.
    Colao A; Spinelli L; Cuocolo A; Spiezia S; Pivonello R; di Somma C; Bonaduce D; Salvatore M; Lombardi G
    J Clin Endocrinol Metab; 2002 Jul; 87(7):3097-104. PubMed ID: 12107207
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The acute effect of a single application of cabergoline on endogenous GH levels in patients with acromegaly on pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Schneider HJ; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2010 Oct; 20(5):338-44. PubMed ID: 20598600
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effects of growth hormone on insulin resistance and atherosclerotic risk factors in obese type 2 diabetic patients with poor glycaemic control.
    Ahn CW; Kim CS; Nam JH; Kim HJ; Nam JS; Park JS; Kang ES; Cha BS; Lim SK; Kim KR; Lee HC; Huh KB
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):444-9. PubMed ID: 16584518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of cortisol metabolism during treatment of acromegaly is independent of body composition and insulin sensitivity.
    Frajese GV; Taylor NF; Jenkins PJ; Besser GM; Monson JP
    Horm Res; 2004; 61(5):246-51. PubMed ID: 15004437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapy of acromegalic patients exacerbated by concomitant type 2 diabetes requires higher pegvisomant doses to normalise IGF1 levels.
    Droste M; Domberg J; Buchfelder M; Mann K; Schwanke A; Stalla G; Strasburger CJ
    Eur J Endocrinol; 2014 Jul; 171(1):59-68. PubMed ID: 24913198
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pegvisomant Improves Glucose Metabolism in Acromegaly: A Meta-Analysis of Prospective Interventional Studies.
    Feola T; Cozzolino A; Simonelli I; Sbardella E; Pozza C; Giannetta E; Gianfrilli D; Pasqualetti P; Lenzi A; Isidori AM
    J Clin Endocrinol Metab; 2019 Jul; 104(7):2892-2902. PubMed ID: 30869797
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
    Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
    Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
    Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
    Jehle S; Reyes CM; Sundeen RE; Freda PU
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1588-93. PubMed ID: 15585549
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Octreotide as primary therapy for acromegaly.
    Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL
    J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies.
    Ma L; Luo D; Yang T; Wu S; Li M; Chen C; Zhou S; Ma L; Wu Y; Zhou Y; Cui Y
    BMC Endocr Disord; 2020 Aug; 20(1):126. PubMed ID: 32811475
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Application of extended hyperinsulinemic euglycemic clamp in the assessment of insulin sensitivity in obese individuals with glucose intolerance].
    Bao YQ; Jia WP; Chen L; Lu JX; Zhu M; Lu W; Xiang KA
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2006 Dec; 28(6):740-4. PubMed ID: 17260458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.